|
1.
|
Goldring SR, Schille AL, Mankin HJ, Dayer
JM and Krane SM: Characterization of cells from human giant cell
tumors of bone. Clin Orthop Relat Res. 204:59–75. 1986.PubMed/NCBI
|
|
2.
|
Zheng MH, Robbins P, Xu J, Huang L, Wood
DJ and Papadimitriou JM: The histogenesis of giant cell tumor of
bone: a model of interaction between neoplastic cells and
osteoclasts. Histol Histopathol. 16:297–307. 2001.PubMed/NCBI
|
|
3.
|
Huang L, Teng XY, Cheng YY, Lee KM and
Kumta SM: Expression of preosteoblast markers and Cbfa-1 and
Osterix gene transcripts in stromal tumor cells of giant cell tumor
of bone. Bone. 34:393–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Sciot R, Dorfman H, Brys P, et al:
Cytogenetic-morphologic correlations in aneurismal bone cyst, giant
cell tumor of bone and combined lesions. Mod Pathol. 13:1206–1210.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Schwartz HS, Eskew JD and Butler MG:
Clonality studies in giant cell tumor of bone. J Orthop.
20:387–390. 2002.PubMed/NCBI
|
|
6.
|
Sawyer JR, Goosen LS, Binz RL, Swanson CM
and Nicholas RW: Evidence for telomeric fusions as a mechanism for
recurring structural aberrations of chromosome 11 in giant cell
tumor of bone. Cancer Genet Cytogenet. 159:32–36. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Forsyth RG, Boeck G, Bekaert S, et al:
Telomere biology in giant cell tumour of bone. J Pathol.
214:555–563. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Lee CH, Espinosa I, Jensen KC, et al: Gene
expression profiling identified p63 as a diagnostic marker for
giant cell tumor of the bone. Mod Pathol. 21:531–539. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Dickson BC, Li SQ, Wunder JS, et al: Giant
cell tumor of bone express p63. Mod Pathol. 21:369–375. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Müller M, Schleithoff ES, Stremmel W,
Melino G, Krammer PH and Schilling T: One, two, three-p53, p63, p73
and chemosensitivity. Drug Resist Updat. 9:288–306. 2006.PubMed/NCBI
|
|
11.
|
Murray-Zmijewski F, Lane DP and Bourdon
JC: p53/p63/p73 isoforms: an orchestra of isoforms to harmonize
cell differentiation and response to stress. Cell Death Differ.
13:962–972. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Ghioni P, Bolognese F, Duijf PH, Van
Bokhoven H, Mantovani R and Guerrini L: Complex transcriptional
effects of p63 isoforms: identification of novel activation and
repression domains. Mol Cell Biol. 22:8659–8668. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Mangiulli M, Valletti A, Caratozzolo MF,
Tullo A, Sbisà E, Pesole G and D’Erchia AM: Identification and
functional characterization of two new transcriptional variants of
the human p63 gene. Nucleic Acids Res. 37:6092–6104. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Moll UM and Slade N: p63 and p73: roles in
development and tumor formation. Mol Cancer Res. 2:371–386.
2004.PubMed/NCBI
|
|
15.
|
Hermanns P and Lee B: Transcriptional
dysregulation in skeletal malformation syndromes. Am J Med Genet.
106:258–271. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Lau CP, Huang L, Tsui SK, Ng PK, Leung PY
and Kumta SM: Pamidronate, farnesyl transferase, and geranylgeranyl
transferase-I inhibitors affects cell proliferation, apoptosis, and
OPG/RANKL mRNA expression in stromal cells of giant cell tumor of
bone. J Orthop Res. 29:403–413. 2011. View Article : Google Scholar
|
|
17.
|
Wulling M, Delling G and Kaiser E: The
origin of the neoplastic stromal cell in giant cell tumor of bone.
Hum Pathol. 34:983–993. 2003.PubMed/NCBI
|
|
18.
|
Robinson D, Segal M and Nevo Z: Giant cell
tumor of bone. The role of fibroblast growth factor 3 positive
mesenchymal stem cells in its pathogenesis. Pathobiology.
70:333–342. 2002.PubMed/NCBI
|
|
19.
|
Lefkimmiatis K, Caratozzolo MF, Merlo P,
et al: p73 and p63 sustain cellular growth by transcriptional
activation of cell cycle progression genes. Cancer Res.
69:8563–8571. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Malaguarnera R, Mandarino A, Mazzon E, et
al: The p53-homologue p63 may promote thyroid cancer progression.
Endocr Relat Cancer. 12:953–971. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Rocco JW, Leong CO, Kuperwasser N, DeYoung
MP and Ellisen LW: p63 mediates survival in squamous cell carcinoma
by suppression of p73-dependent apoptosis. Cancer cell. 9:45–56.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Sbisà E, Mastropasqua G, Lefkimmiatis K,
Caratozzolo MF, D’Erchia AM and Tullo A: Connecting p63 to cellular
proliferation: the example of the adenosine deaminase target gene.
Cell Cycle. 5:205–212. 2006.PubMed/NCBI
|
|
23.
|
Crook T, Nicholls JM, Brooks L, O’Nions J
and Allday MJ: High level expression of deltaN-p63: a mechanism for
the inactivation of p53 in undifferentiated nasopharyngeal
carcinoma. Oncogene. 19:3439–3444. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Senoo M, Tsuchiya I, Matsumura Y, et al:
Transcriptional dysregulation of the p73L/p63/ p51/p40/KET gene in
human squamous cell carcinomas: expression of Delta Np73L a novel
dominant-negative isoform and loss of expression of the potential
tumor suppressor p51. Br J Cancer. 84:1235–1241. 2001. View Article : Google Scholar
|
|
25.
|
Hibi K, Trink B, Patturajan M, et al: AIS
is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad
Sci USA. 97:5462–5467. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Park BJ, Lee SJ, Kim JI, et al: Frequent
alteration of p63 expression in human primary bladder carcinomas.
Cancer Res. 60:3370–3374. 2000.PubMed/NCBI
|
|
27.
|
Taniere P, Martel-Planche G, Saurin JC,
Lombard-Bohas C, Berger F, Scoazec JY and Hainaut P: TP53 mutations
amplification of P63 and expression of cell cycle proteins in
squamous cell carcinoma of the oesophagus from a low incidence area
in Western Europe. Br J Cancer. 85:721–726. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Zaika AI, Kovalev S, Marchenko ND and Moll
UM: Overexpression of the wild-type p73 gene in breast cancer
tissues and cell lines. Cancer Res. 59:3257–3263. 1999.PubMed/NCBI
|
|
29.
|
Zaika AI, Slade N, Erster SH, et al:
DeltaNp73, a dominant-negative inhibitor of wild-type p53 and
TAp73, is up regulated in human tumors. J Exp Med. 196:765–780.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Tannapfel A, Schmelzer S, Benicke M, et
al: Expression of the p53 homologues p63 and p73 in multiple
simultaneous gastric cancer. J Pathol. 195:163–170. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Wong KC, Kumta SM, Tse LF, Ng EW and Lee
KS: Navigation Endoscopic Assisted Tumor (NEAT) surgery for benign
bone tumors of the extremities. Comput Aided Surg. 15:32–39. 2010.
View Article : Google Scholar : PubMed/NCBI
|
